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Perinatal brain injury frequently complicates preterm birth and leads to signiﬁcant long-term morbidity. Cytokines and
inﬂammatory cells are mediators in the common pathways associated with perinatal brain injury induced by a variety of insults,
such as hypoxic-ischemic injury, reperfusion injury, toxin-mediated injury, and infection. This paper examines our current
knowledge regarding cytokine-related perinatal brain injury and speciﬁcally discusses strategies for attenuating cytokine-mediated
brain damage.
1.Introduction
Preterm birth aﬀects 12.5% of pregnancies in the United
States [1, 2] and is the leading cause of neonatal morbidity
and mortality, accounting for nearly half of the long-
term neurologic morbidity in children [3]. The majority of
premature infants in developed countries survive; however,
5–10% of survivors develop cerebral palsy (CP), and 40–
50% develop cognitive and behavioral deﬁcits [4, 5]. The
prolonged vulnerability of the developing white and gray
matter to excitotoxic, oxidative, and inﬂammatory forms of
injury is a major factor in the pathogenesis of perinatal brain
injury. While acute catastrophic brain injuries sometime
occur (e.g., severe intraparenchymal hemorrhage), injury
to white and gray matter regions is most often the cumu-
lative result of metabolic, infectious and/or inﬂammatory,
and hypoxic-ischemic insults over time [6]. For example,
early respiratory compromise and systemic hypotension can
precipitate glutamate, free radical, and cytokine toxicity
to developing oligodendrocytes and neurons. The clinical
course might be further complicated by late-onset or
necrotizing enterocolitis (NEC). These sequential events
result in diﬀerent topographic patterns of injury based on
developmental and genetic susceptibilities.
Although there has been much focus on white matter
injury (WMI) in premature infants, gray matter abnormal-
ities in cortical and deep nuclear structures, and cerebellar
injuries are also common and likely contribute to develop-
ment of cognitive delay, psychomotor delay, and CP [7]. A
varietyofincitingeventssuchashypoxic-ischemia,infection,
and/or inﬂammation, can stimulate a cascade of secondary
responses, including ﬂuid-electrolyte imbalance, regional
blood ﬂow alterations, calcium-mediated cellular injury,
free-radical generation, oxidative and nitrosative stress,
glutamate-inducedexcitotoxicity,disturbancesinproinﬂam-
matory cytokine production, mitochondrion function, and
apoptotic cell death [6, 8]. These disturbances result in acti-
vation of inﬂammatory cells involved in the innate immune
response including neutrophils, macrophages, and resident
microglia, which may propagate brain injury through mech-
anisms that directly and indirectly lead to neuronal and
preoligodendrocyte (preOL) cell death or dysfunction.
Cytokines and inﬂammatory cells are mediators in the
common pathways associated with perinatal brain injury
inducedbyavarietyofinsults[9–12].Abetterunderstanding
of the role of cytokines in perinatal brain injury is needed
to facilitate the development of strategies to prevent and/or
treat cerebral white and gray matter damage.2 Neurology Research International
2.CytokinesAffecting the Fetus
andNeonate:WhatAreTheyand
Where Do They Come From?
Cytokines are small, cell signaling nonstructural proteins
involved in regulating hematopoiesis, inﬂammation, and
immune cell proliferation and diﬀerentiation. They are
grouped into diﬀerent classes based on biological activity
[13]. The term cytokine encompasses a variety of soluble
proteins including monokines, interleukins (IL), colony-
stimulating factors,interferons(IFNs), tumornecrosis factor
(TNF), and chemokines [14]. These messenger molecules
link the neural, endocrine, and immune systems [15].
Cytokinescanbepro-oranti-inﬂammatory,neuroprotective
or destructive, depending on their state and concentration
[16]. Although nearly all nucleated cells produce cytokines,
they are mainly produced by glial cells in the central nervous
system (CNS) or by immune cells, such as helper T cells and
macrophages [14]. Stimuli inducing cytokine production
may originate remote to, or within the CNS. The origin
of cytokines acting within the CNS may include blood-
borneandnativeCNSsources,includingimmunecells,brain
endothelial cells, astrocytes, microglia, and neurons [17–19].
Cytokines act by binding to speciﬁc cell surface receptors,
which then induce intracellular signaling mechanisms that
up- or downregulate transcription factors, leading to pro-
or anti-inﬂammatory reactions. Cytokines with generally
proinﬂammatory properties include TNF-α,I N F - γ,I L - 1 ,I L -
6, and IL-18, while cytokines that antagonize the proinﬂam-
matory responses include IL-1 receptor antagonist, IL-4, IL-
6, IL-10, IL-11, and IL-13, and transforming growth factor
(TGF)-β. Soluble receptors for proinﬂammatory cytokines
can have similar function. Note that IL-6 appears in both
categories.
3. Differences in Neonatal and
Adult ImmuneResponses
The immune system of the fetus and newborn reﬂects the
unique interaction between the developing individual and its
host-mother. The developing fetus must avoid precipitating
a maternal immune response that results in rejection or
preterm delivery, but still must protect itself from intrauter-
ine infection and prepare for the transition from the sterile
intrauterine environment to the extrauterine environment
that is rich with antigenic challenges. This combination of
factors results in a neonatal immune system that diﬀers
signiﬁcantly from its adult counterpart. In comparison to
adults, the neonatal immune response is biased towards a
Th2 response, with a muted Th1 response [20]. Stimulated
neonatal mononuclear cells secrete markedly less of the pro-
inﬂammatory Th1-polarizing cytokines, TNF-α and IFN-γ,
whereas secretion of IL-6, a cytokine with anti-inﬂammatory
and Th2-polarizing properties, is actuallygreater in neonates
than adults. This response is mediated by adenosine, an
endogenous purine metabolite with immune-modulatory
properties [21–23].
4.Barriersto Accessingthe Brain
There are three interfaces where molecular and cellular
exchange between blood and neural tissues or the cerebral
spinal ﬂuid occurs. These are the blood brain barrier (BBB)
formed by the cerebrovascular endothelial cells between
blood and brain interstitial ﬂuid, the choroid plexus epithe-
liumbetween blood and ventricularCSF(blood-CSF barrier,
BCSFB) and the arachnoid epithelium between blood and
subarachnoid CSF [24, 25]. The two barriers that represent
the largest interface between blood and brain extracellular
ﬂuids are the BBB, formed by brain endothelial cells, and the
BCSFB, formed by choroid plexus epithelial cells (Figure 1)
[26].TheBBB,alsotermedthe“neurovascularunit,”consists
of highly specialized endothelial cells interconnected by an
elaborate network of complex tight junctions surrounded by
basal lamina in which pericytes and perivascular antigen-
presenting cells are embedded, with an outer ensheathment
of astrocytic perivascular endfeet. Mast cells, which synthe-
size and store neuroactive and vasoactive substances, are
located at perivascular locations on the brain side of the
BBB in apposition with astrocytic and neuronal processes
[27]. In addition to tight junctions, adherens junctions hold
the endothelial cells together providing structural support
required for formation of tight junctions and are necessary
to prevent disruption of the BBB [26]. The astrocytes that
surround the microvasculature provide the cellular link to
the neurons and play an active role in signal transduction
pathways and regulating the BBB [24]. In adults, there are
ﬁve known routes by which materials can pass between the
circulation and the brain across these barriers (Figure 2)
[25]. These are via a paracellular aqueous pathway (across
tight junctions) and through transcellular pathways includ-
ing the lipophilic pathway, via transport proteins, receptor-
mediated transcytosis, or adsorptive transcytosis [25, 28].
Whether these same mechanisms are active in the fetus and
neonate remains unknown.
From the earliest stages of brain development, the BBB
excludes the passage of protein and small lipid insoluble
markers between the circulating blood and the brain extra-
cellular ﬂuid [32, 33]. Similarly, paracellular diﬀusion of
protein and small, lipid-insoluble molecules is limited at
the BCSFB by apical tight junctions between the choroid
plexus epithelial cells [34]. However, these substances may
passbytranscellularmechanismsinchoroidplexusepithelial
cells, and their permeability is much higher in imma-
ture compared to adult brain [35]. Stolp et al. studied
BBB permeability resulting from lipopolysaccharide-(LPS-)
induced systemic inﬂammation (deﬁned as increased blood
concentrations of acute-phase proteins or IL-1β and TNF-α)
in rats and opossums [33]. They demonstrated a restricted
period in brain development when protein permeability of
the BBB, but not the BCSFB, is altered following systemic
inﬂammation. This increased BBB permeability was speciﬁc
to white matter and was related to stage of development and
not BBB immaturity.
The BBB is a dynamic structure which can be modiﬁed
by circulating factors or by chemicals secreted by cells
associated with the BBB [25]. Agents known to impair adultNeurology Research International 3
Figure 1: The blood-brain and the blood-cerebrospinal ﬂuid barriers. A schematic diagram of the two barriers that represent the largest
interface between blood and brain extracellular ﬂuids: the brain endothelium forming the blood-brain barrier (BBB), also referred to as the
neurovascular unit, and the choroid plexus epithelium forming the blood-cerebrospinal ﬂuid (CSF) barrier. The neuroependymal surface
lining of the ventricular system (inner CSF-brain barrier) is unique to the fetal brain and is not present in the adult. The neuroependymal
cells are connected by “strap junctions” that prevent exchange of large molecules such as proteins between the CSF and brain [31]. Tight
junctions and adherens junctions limit paracellular pathway endothelium and epithelium permeability. The neurovascular unit consists of
specialized endothelial cells interconnected by tight junctions surrounded by basal lamina in which pericytes are embedded, with an outer
ensheathment of astrocytic perivascular endfeet. Mast cells are located at perivascular locations in apposition with astrocytic and neuronal
processes [27]. Inﬂammation may result in disruption of tight junctions and adherens junctions leading to paracellular passage of cytokines.
BBB function (increase leakiness) include bradykinin, his-
tamine, serotonin, glutamate, purine nucleotides (ATP, ADP,
AMP), adenosine, platelet-activating factor, phospholipase
A2, arachidonic acid, prostaglandins, leukotrienes, inter-
leukins (IL-1α,I L - 1 β,I L - 6 ) ,T N F α, macrophage-inhibitory
proteinsMIP1andMIP2,freeradicals,andnitricoxide(NO)
[25]. Many of these agents are upregulated after hypoxia or
during infection.
It is not surprising then that localized or systemic
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Figure 2: Access pathways across the cerebrovascular endothelial cells. An illustration depicting purposed access routes of materials across
the endothelial cells of the blood-brain barrier (BBB). The pathways for cellular molecular movement from the circulation across the
BBB may include (a) paracellular aqueous pathway across tight junctions, (b) transcellular pathways including the lipophilic pathway, (c)
transportproteins,(d)receptor-mediatedtranscytosis,and(e)adsorptivetranscytosis.Cytokinetraﬃckingmayoccurviareceptor-mediated
transcytosisorpossiblyacrossdisruptedtightjunctionsinthesettingofinﬂammation.Cytokinemovementisthoughttooccurmainlyinthe
blood-to-brain direction; however, in the blood-cerebrospinal ﬂuid barrier, bulk ﬂow movement may lead to cytokine absorbtion into blood
[19]. Mononuclear cells may penetrate the BBB by a process of transcellular diapedesis, directly through the cytoplasm of the endothelial
cells without tight junction disruption [29]. During proinﬂammatory conditions, tight junctions between endothelial cells may be disrupted
allowing mononuclear cells to gain access from the blood to the brain via paracellular routes, along with cytokines [30].
fetal inﬂammatory response) remote to the CNS may result
in disruption of the BBB/BCSFB with increased cytokine
access to the CNS [36, 37]. Activated CD4+ T lymphocytes,
macrophages and dendritic cells must cross the endothelial
and the parenchymal basement membranes and glia limitans
before gaining direct access to the brain. Transmigration
of these cytokine-producing immune cells appears to be
inﬂuenced by ultrastructural alterations in the laminin iso-
form composition of the endothelial basement membrane,
and by focal matrix metalloproteinase (MMP) activity of
the parenchymal basement membrane [24]. To breach to
BCSFB, circulating cytokines/immune cells must migrate
across the fenestrated choroid plexus capillaries, enter the
outer CNS parenchyma, and then penetrate the choroid
plexus epithelial cell layer either by passing through the
parallel tight junctions strands or transcellularly through
the choroid plexus epithelial cells. However, evidence of
inﬂammatory mediator access to the CNS across the BCSFB
in the human fetus/neonate remains undeﬁned.
The role of the neurovascular unit, which includes
cellular (endothelial and epithelial cells, astrocytes, and
pericytes) and acellular (e.g., the extracellular matrix net-
works) barriers in regulating cytokine access beyond the
BBB and BCSFB to the CNS needs to be clariﬁed in
order to understand potential opportunities to mitigate
the inﬂammatory cascade associated with perinatal brain
injury. There is a paucity of information on in vivo human
fetal/neonatal properties of barrier dysfunction and the
availableinvitroandadultanimalmodelsmaynotaccurately
reﬂect neurovascular unit functional permeability following
injury/inﬂammation. For example, although experimental
studies have demonstrated that LPS can induce WMI and
neuroinﬂammation [38], evidence that LPS gains access
to the fetal/neonatal brain causing human perinatal brain
damage is lacking. However, since microglial cells possess
LPS-binding toll-like receptor (TLR)4 receptors and seem
to be necessary for LPS-induced oligodendrocyte death
[39] this suggests that LPS can gain access to the brain.
Additionally, how proinﬂammatory cytokines aﬀect cellular
inward and outward CNS barrier transfer mechanisms and
alter CNS barrier function potentially inﬂuencing perinatal
braininjuryremainsunknown.Identifyingperiods whenthe
fetal/neonatal CNS is vulnerable to inﬂammatory mediator-
induced barrier disruption and subsequent damage due to
CNS penetration of peripheral toxic molecules is needed in
ordertodeﬁnepharmacologictherapeuticwindowstoaccess
injured brain regions.
The BBB can act as a regulatory conductor between
the CNS and the peripheral circulation, establishing and
maintaining CNS homeostasis, moderating the nutritional
needs of the CNS, and governing inﬂux and eﬄux of
signalingmolecules[19].TheBBBappearstohaveadualrole
in regulating immune cell traﬃcking between the CNS and
blood by controlling restrictive and selective permeabilityNeurology Research International 5
[40]. Cytokines can disrupt the BBB [41, 42]a n dB C S F B ,
[43] and also can alter saturable neuropeptide transporter
[44] and ATP-driven drug eﬄux pump activity [45] without
aﬀecting BBB integrity. The BBB can secrete cytokines [46–
49]andmayactivelyparticipateininﬂammatoryreactionsof
the CNS. Dysfunction of BBB and BCSFB mechanisms may
be more than just a consequence of inﬂammation/injury, but
also may constitute part of the disease process. Increased
blood-spinal barrier permeability following spinal cord
trauma involves an active upregulation in inﬂammatory
cytokine transport systems in endothelial cells around the
injured area [50]. Immune mediator traﬃc regulated by the
BBB may also play a role in recovery following injury, as
has been demonstrated in a murine model of hypothermic
brain injury in which macrophages promote early posttrau-
matic reformation of the BBB [51]. The type and amount
of cytokines transported across the BBB varies by CNS
region, implying that there are diﬀerent cytokine-speciﬁc
regulatory mechanisms and eﬀects [19]. Whether the human
fetal/neonatalBBBalsoplaysanactiverole(similartoanimal
models) not only in ongoing tissue damage, but also in the
recovery process following CNS injury is not clear.
5. Infection
An in utero infection such as chorioamnionitis may trig-
ger an innate immune system response, resulting in ele-
vated cytokine levels. Microorganisms express conserved
sequences known as pathogen-associated molecular patterns
(PAMPs), such as LPS and double stranded RNA, on their
surfaces. Recognition of these PAMPs by pattern recognition
receptors on immune cells stimulate speciﬁc host cell TLRs
[20]. For example, when stimulated by LPS, TLR4 signals
through the adapter molecule myeloid diﬀerentiation factor
88, to activate the nuclear factor-κB( N F - κB) pathway that
leads to an immune response characterized by the produc-
tion of cytokines, antimicrobial products, and the regulation
of costimulatory molecules [52]. The cytokine response
may progress from the trophoblast, decidua, and amniotic
epithelium [53, 54], to the amniotic ﬂuid [55, 56] to the
fetallungsandthenbloodstream,orbydirecthematogenous
spread via the maternal-placental-fetal circulation. Initiation
of a proinﬂammatory cytokine response following bacterial
infection of placental tissues can lead to preterm labor
[57]. Cytokines associated with preterm labor include IL-1β
[58], IL-6 [59], IL-8 [60], and TNF-α [61]. Activated im-
mune cells including circulating neutrophils, phagocytic
macrophages, T cells, and NK cells, and resident CNS astro-
cytes and microglia produce biological mediators including
cytokines, chemokines, adhesion molecules, and growth
factors involved in complex intermolecular interactions that
participate in the immunoinﬂammatory processes related to
brain injury [62]. Cytokines in the fetal blood stream may
contribute to a systemic fetal inﬂammatory response with
eventual penetration across the BBB resulting in a chemical




Interaction between the CNS and the immune system relies
on the expression of several cytokines and their receptors in
both neurons and glial cells in the brain [63]. The two major
reactive glial cell types that play signiﬁcant roles during
CNS injury and repair are microglia and astrocytes. These
glial cells are involved in the intracerebral immune response
where they act, in part, by secreting cytokines, chemokines,
neurotrophic, or neurotoxic factors [64]. Cytokines and
their receptors, like IL-1β and IL-1β receptor protein, are
constitutively expressed in the CNS by astroglia, microglia,
and oligodendrocyte progenitor cells (OPCs) [65].
Astrocytes are important players in neuroinﬂammatory
processes and are capable of producing numerous cytokines
including a variety of interleukins, TNF-α, and members of
the interferon family [66]. The involvement of astrocytes in
the pathogenesis of WMI is suggested by increased cytokine
expression (IL-1β,I L - 6 ,a n dT N F - α) in both the diﬀuse and
focalcomponentsofperiventricularleukomalacia(PVL)[67,
68].Activatedmicrogliaproducecytokines,chemokines,free
radical species, proteases, and other potential mediators of
injury [69, 70]. Upon stimulation by LPS, microglia express
IL-1β, which triggers astrocyte expression of tissue inhibitors
of metalloproteinases (TIMPS) [71]. During CNS injury
and repair, TIMPS play a critical role in regulating tissue
proteolysis by neutralizing the eﬀect of the MMP. TIMP-1 is
involvedinregulatingthegrowthandmorphologyofcortical
neurons in an MMP-dependent manner [72] and plays a role
in oligodendrocyte generation and diﬀerentiation [73, 74].
Furtherstudiesareneededtodeterminetheroleofmicroglial
IL-1β cytokine signaling and TIMP expression in perinatal
brain inﬂammation and repair.
7.BrainInjuryAssociatedwithPrenatal
Infection and/or Inﬂammatory Insults
Intrauterine infection might account for 25–40% of preterm
births with up to 80% of preterm deliveries at <30 weeks
of gestation having evidence of infection [75]. Clinical
chorioamnionitis is signiﬁcantly associated with cystic PVL
and CP [76]. Neonates exposed to clinical chorioamnionitis
or histological chorioamnionitis have increased risks of
140%and80%fordevelopingCP,respectively[77].Bacterial
infection of the decidua and placental membranes activates
TLRs on the surface of inﬂammatory cells which results in
release of proinﬂammatory cytokines, and initiates a local
inﬂammatory reaction in the placenta [78, 79]. Elevated IL-6
concentrations measured in cord blood from neonates with
white matter lesions associated with PVL supports the role
of intrauterine inﬂammation and subsequent WMI [80].
Perinatal brain injury may not be contingent on pathogen
penetration into the fetal CNS: intrauterine exposure to
a systemic inﬂammatory stimulus alone can lead to brain
damage in preterm neonates [10, 81].
Chorioamnionitis can be classiﬁed into acute and
chronic chorioamnionitis [82]. Acute chorioamnionitis of6 Neurology Research International
infectious origin is associated with elevated amniotic ﬂuid
IL-6 levels and results from microbial invasion of the amni-
otic cavity and intrauterine infection. Chronic chorioam-
nionitis of immunological origin is associated with elevated
amniotic ﬂuid CXCL10 levels and is a possible consequence
of disrupted immune system hormones aﬀecting CD8+
T-cell activity resulting in maternal antifetal rejection.
Amniotic ﬂuid proteomic analysis has demonstrated that
acute chorioamnionitis and chronic chorioamnionitis are
likely manifestations of diﬀerent pathological processes [82].
Whether acute versus chronic chorioamnionitis also result in
distinct alterations in perinatal brain injury patterns is not
known.
8.BrainInjuryAssociatedwithPostnatal
Infection and/or Inﬂammatory Insults
In preterm infants, known inﬂammatory conditions are
associated with WMI. These include both early- [83]a n d
late-onset sepsis [84], as well as NEC [85] and are generally
associated with high plasma levels of IL-6, IL-8, and TNF-α
[86]. Bronchopulmonary dysplasia, another comorbidity of
prematurity, is associated with evidence of inﬂammation
(neutrophils, macrophages, cytokines and toxic oxygen rad-
icals) [87] and is also associated with increased risk of WMI
[88].
9. Cytokines and Cerebral Palsy
CP, the most common cause of severe physical disability
in childhood [89], is an umbrella term describing multiple
diseases originating early in life characterized by variable
motor impairments secondary to unspeciﬁed etiologies and
cerebral pathologies. Preterm birth, perinatal infection, and
neonatal encephalopathy are important risk factors for the
development of CP [90].
9.1. Preterm Infants. Periventricular WMI is an important
cause of disability in preterm low-birth-weight infants. Prior
to 32 weeks of gestation, preOLs are particularly vulnerable
to injury and developmental arrest [91]. Injury to these cells
can result in a cystic necrosis of white matter tracts and/or
diﬀuse noncystic lesions with hypomyelination [6]. Injury
most commonly occurs in a watershed, periventricular
distribution, which typically corresponds clinically with
spastic diplegia, the most common form of CP diagnosed
in preterm infants [92, 93]. Inﬂammation, mediated by
proinﬂammatory cytokines, can contribute to the WMI that
occurs in preterm infants [94]. In a study of 96 preterm
babies with gestational age ≤32 weeks, elevated umbilical
cord blood IL-8 concentrations were associated with CP
(diagnosed by followup at 1 year of age) [95]. Another large
multicenter study of infants with birth weights ≤1000g (n =
1067) demonstrated that circulating IL-8 concentrations
were higher on days 0–4 and subsequently in infants who
developed CP compared with infants who did not develop
CP in both unadjusted and adjusted analyses [96].
Macrophage inﬁltration and high levels of TNF-α and
IL-1β have been demonstrated in brains of neonates with
PVL compared to neonates with anoxic lesions who died
shortly after birth [67]. These high cytokine concentrations
may have direct cytotoxic eﬀects on oligodendrocytes [97].
Neuronal cytotoxicity following exposure of preOLs to
LPS is mediated by activated microglia via TLR-associated
signaling pathways [98]. Both focal and diﬀuse forms of
PVL are associated with activated microglia [8]. The release
of proinﬂammatory cytokines from activated microglia has
been implicated in neuronal and glia cell death [99]. Pang
et al., using primary OPC cultures prepared from neonatal
rat optic nerves, demonstrated that LPS-activated microglia
mediate OPC death by two distinct mechanisms in a time-
dependent manner [100]. An early phase of OPC damage
occurs within 24h after LPS treatment, mediated by NO-
dependent oxidative damage, and a delayed phase of OPC
death, evident at 48h after LPS treatment, is mediated
by cytokines and is prevented by blocking TNF-α activity.
Whether these two distinct mechanisms of injury occur in
human perinatal brain injury leading to PVL is not clear.
Inﬂammatory processes originating during vulnera-
ble periods of neurodevelopment may result in perinatal
programming. The eﬀects of inﬂammation triggered by
proinﬂammatory cytokines, prostaglandins, or LPS on the
developing CNS of premature infants may have long-term
consequences for the individual’s ability to cope with envi-
ronmental exposures during childhood and adulthood [36].
Lin et al. demonstrated that school-age preterm children
with PVL-induced CP had signiﬁcantly higher plasma con-
centrations of TNF-α, increased TNF-α released from LPS-
stimulated peripheral blood mononuclear cells (PBMCs),
and mRNA expression of inﬂammatory signaling molecules,
including TLR4 and TNF-α, in PBMCs compared to normal
control school-age preterm children [101]. Additionally,
intracellular PBMC TNF-α levels were signiﬁcantly higher
in children with CP, but lower in controls following LPS
stimulation.WhetherornotchildrenwithCPwhowereborn
preterm with a history of PVL have long-term abnormalities
of their immune responses remains unclear.
9.2. Cytokines, CP, and Neonatal Encephalopathy. Maternal
inﬂammation contributes signiﬁcantly to fetal susceptibility
to hypoxia-ischemia [102–104] and the subsequent devel-
opment of CP [105, 106]. Hypoxia-ischemia and infection
canbothinduceasystemicinﬂammatoryresponseassociated
with elevated cytokines [94, 107]. Higher concentrations of
IL-1β,I L - 6 ,T N F - α, and IL-8 in the blood of neonates who
have encephalopathy have been associated with increased
anaerobic brain metabolism, and with abnormal neurode-
velopmental outcome [108]. Elevated concentrations of
IL-6 and IL-8 have been demonstrated in the CSF of
asphyxiated full-term infants, with intrathecal levels of these
cytokines corresponding to the degree of hypoxic-ischemic
encephalopathy [109].
Term neonates with encephalopathy have a risk for CP
that is 100 times that of those infants who do not have
encephalopathy [10]. Increased concentrations of IL-1β,Neurology Research International 7
IL-6 and TNF-α in amniotic ﬂuid [98], and IL-6 in cord
blood [74, 110] secondary to maternal, placental, or fetal
infections [97, 111] are associated with cerebral WMI and/or
CP. Similarly, elevated neonatal blood concentrations of IL-6
and IL-8 were associated with the diagnosis of CP at 1 year of
age in a study of 73 term babies (gestational age ≥36 weeks)
[9].
Although infection and/or inﬂammation increase the
risk for CP, they may not be suﬃcient causal factors to
induce brain damage. In a 3-year follow-up study of high-
risk infants, Yoon et al. reported that CP was diagnosed in
only 18% (5/28) of infants born with documented microbial
invasion of the amniotic cavity and 24% (11/45) of infants
with evidence of intrauterine inﬂammation [112]. Another
study compared early blood concentrations of inﬂammatory
cytokines(IL-1,-6,and-8andTNF-α)from64childrenlater
diagnosed with CP to 107 control children (all born at <32
weeks gestational age). Early cytokine concentrations were
not predictive of later CP [104].
10.Dual-Role Cytokines
Inﬂammation in the CNS can result in signiﬁcant brain
damage, including injury to axons and myelin, the loss
of preOLs, oligodendrocytes, and neurons [69]. However,
neuroinﬂammation can be also be beneﬁcial, promoting
neuroprotection, the mobilization of neural precursors for
repair, remyelination, and even axonal regeneration [69].
Some cytokines can have both pro- and anti-inﬂammatory
eﬀects. For example IL-4, IL-10, and IL-13 are potent acti-
vators of B lymphocytes, and also potent anti-inﬂammatory
agents with the ability to suppress expression of proinﬂam-
matory cytokines IL-1 and TNF [13]. TNF-α and IL-1β can
have both neuroprotective and damaging eﬀects [113]. IL-
6 and IL-8, typically associated with inﬂammation, have
been associated with the release of nerve growth factor in
the CSF of patients with traumatic brain injury suggesting
their role in promoting repair of the CNS lesions as well as
of axonal regeneration [16]. A dual role can also be seen
in macrophages, which are key mediators of the immune
response, particularly regarding their ability to produce
cytokines. Macrophages can be subdivided into subtypes
(M1 and M2) with M1 macrophages considered proinﬂam-
matory, producing molecules such as TNF-α, IL-1, IL-6,
and NO, while the M2 subset is typically considered anti-
inﬂammatory, producing molecules like IL-10, TGF-β,a n d
IL-1 receptor antagonist [69]. The neuroimmune response
appears to be dichotomous with the balance of pro- and
anti-inﬂammatory cytokines likely inﬂuencing neurodevel-
opmental outcomes. Further research is needed to clarify
what inﬂuences cytokines (e.g., timing, type, location, and
durationofinjury)topromotepeaceorwagewarwithregard
to neuroprotection and neuroinﬂammation, respectively.
11.CytokinesandGeneticSusceptibilityto
Perinatal Brain Injury
Susceptibility to perinatal brain injury may be partially
genetically determined by the balance of proinﬂamma-
tory and anti-inﬂammatory cytokine expression. Single-
nucleotide polymorphisms in genes encoding cytokines and
their receptors might positively or negatively aﬀect the risk
of perinatal brain injury in infants. An increased risk for
WMI has been associated with IL-8, IL-6, TNF-α, and TLR4
polymorphisms [10, 114].
Arecentmeta-analysisbyWuetal.demonstratedthatCP
is associated with IL-6 genetic polymorphisms [115]. Mod-
erately preterm infant (32–36 weeks’ gestational age) carriers
of IL-6 gene −174C allele, associated with upregulated IL-
6 expression, may have an increased risk of developing
quadriplegicCP[114].FunctionalpolymorphismintheIL-6
gene(−174CCgenotype)amongtermandnear-terminfants
has been associated with an attributable risk percentage
of 11.6% for developing CP [116]. The development of
hemiplegicandquadriplegicCPhasbeendemonstratedwith
IL-6orIL-4polymorphismsinthepresenceofviralexposure
suggesting an association between candidate cytokine poly-
morphisms and a fetal inﬂammatory environment, which
may be causally linked to the risk of CP development
[114]. This proposed “double jeopardy” hypothesis linking
neurotropic viral exposure and genetic susceptibility to
infection needs further conﬁrmation in susceptible neonatal
population studies to establish causation of CP. In contrast,
t h e r em a yb ep r o t e c t i v eg e n ep o l y m o r p h i s m s .F o re x a m p l e ,
preterm infants (<32 weeks gestation) homozygous for the
high IL-10 producer −1082G allele are signiﬁcantly less
likely to develop ultrasound deﬁned PVL [117].
12. Cytokine Biomarkers of
Perinatal Brain Injury
Accurate diagnostic, predictive, and prognostic biomarkers
of brain injury are needed for optimizing the clinical treat-
ment of at-risk neonates. Ideal biomarkers would accurately
reﬂect the degree of brain injury, the timing and evolution
of injury, and potential for response to therapy. These
biomarkers would help to diﬀerentiate infants who do not
require treatment from those at risk of permanent sequelae;
infants that might beneﬁt from intervention from those for
whom treatment is futile and identify infants who are within
a therapeutic window for a speciﬁc treatment. It is unlikely
that a single biochemical or imaging biomarker measured
at a single time point will achieve all these goals. Magnetic
resonance imaging (MRI) and spectroscopy (MRS) have
shown promise, but the most predictive protocols and the
optimal timing of studies is still not fully established [118].
Measurement of inﬂammatory proteins in blood, includ-
ing cytokines, shortly after birth in preterm infants may
provide information about the risk of sonographic WMI
(which correlates with neurodevelopmental outcome). Serial
measurements of blood proteins during the ﬁrst 2 postnatal
weeks in extremely low gestational age newborns (born
before the 28th week of gestation) in the ELGAN study
demonstrated an increased risk of ventriculomegaly, sono-
graphic indicator of diﬀuse cerebral WMI, in association
with elevated concentrations of vascular endothelial growth8 Neurology Research International
factor receptor 1, serum amyloid A, and macrophage inﬂam-
matory protein 1β o nd a y1a n dI L - 8o nd a y7[ 119]. An
increased risk of an echolucent lesion, a sonographic indi-
cator of focal cerebral white matter damage, was associated
with elevated concentrations of macrophage inﬂammatory
protein 1β on day 1 and intercellular adhesion molecule 1
on day 7 [119]. Interestingly, in this same study, elevated
concentrationsof thechemokine Regulatedupon Activation,
Normal T-cell Expressed, and Secreted (RANTES, also
known as CCL5) was associated with reduced risk of both
ventriculomegaly and echolucent lesions. RANTES down-
regulates TLR4 ligation-induced IL-6 and TNF-α secretion
by enhancing IL-10 production in PBMCs [120]a n dm a y
play an anti-inﬂammatory role in perinatal brain injury.
Elevated cytokine levels have been associated with peri-
natal brain injury and show promise as diagnostic and/or
prognostic biomarkers to be used in a multimodal approach
along with MRI. Elevated levels of IL-1β,I L - 6 ,I L - 8 ,a n d
lower levels of IL-12 following term delivery in infants
with neonatal encephalopathy has been associated with
impaired cerebral oxidative metabolism based on MRS and
abnormal neurodevelopmental at 30 month of age, but
not with detectable MRI changes in the neonatal period
[108]. Procianoy and Silveira reported on the association
between high cytokine concentrations with WMI in preterm
infants and sepsis, looking at cohort of 84 very-low-birth-
weight infants, 27 (32%) with WMI, and 57 (68%) control
subjects (no WMI). WMI was increased in infants with
clinical early-onset sepsis and higher plasma levels of IL-
8, IL-6, and TNF-α.I L - 8l e v e l s≥100pg/mL had sensitivity
96%, speciﬁcity 83%, and negative predictive value 98%
indicating that this chemokine may be a good predictor of
WMI [86]. Although elevated levels of CSF cytokines have
been associated with WMI, plasma cytokine concentrations
may not reﬂect CSF cytokine levels or inﬂammatory events
withinthebrain[94].Therefore,relyingonplasmacytokines
as biomarkers of perinatal brain injury may prevent early
recognition of localized brain inﬂammation. Additionally,
measuring cytokines to assess perinatal brain injury has not
been done routinely in the NICU setting and will likely
require lowercost, automated, on-demand testing before
these potential biomarkers are incorporated into standard
diagnostic testing. Multiple assessments of these values over
time may provide more accurate predictive values.
13. Prevention and Treatment of
Perinatal Brain Injury
There are few interventions currently available to prevent
or treat perinatal brain injury. Currently used strategies
known to improve the outcome of prematurity include
maternal prenatal treatments with magnesium sulfate and
betamethasone, and postnatal neonatal use of caﬀeine.
The only proven therapy available for term and near
term infants with neonatal encephalopathy is therapeutic
hypothermia. There are other promising therapies under
active investigation for prevention and treatment of neonatal
brain injury, including melatonin, erythropoietin (Epo),
N-acetylcysteine, Epo mimetics, allopurinol, and xenon.
Some of these approaches target anti-inﬂammatory mech-
anisms, and still others improve BBB function, thereby
preventing the passage of cytokines and other potentially
injuriousfactorsintothebrain.Examplesofsuchapproaches
are explored below.
13.1. Erythropoietin. E p oi sah e m o p o i e t i cg r o w t hf a c t o r
produced by all vertebrates. Functional receptors for Epo
are present on cell types other than erythrocyte progenitors,
includingneurons,andmanyglialcelltypes.Epoisapromis-
ing novel neuroprotective agent. It is widely available, aﬀord-
able, and has been safe in over 25 years of neonatal studies
of erythropoiesis. Epo triggers several diﬀerent signaling
pathwaysafterbindingtoitsreceptor.Neuroprotectiveeﬀects
areassociatedwithactivationofJanuskinase/Stat5andNFkB
pathways [121], while Stat5 and Akt pathways are required
for neurotrophic eﬀects of Epo [122]. Epo also stimulates
expression of several growth factors, including vascular
endothelial growth factor secretion (VEGF) [123] and brain-
derived neurotrophic factor (BDNF) [124], which may be
beneﬁcial in the injured brain. There are extensive data to
support its neuroprotective eﬀects in vitro, and in neonatal
models of brain injury [125–131]. Epo has anti-apoptotic
[128, 129] and anti-inﬂammatory eﬀects (decreased Il-6 and
IL-8) [132, 133], and it also increases neurogenesis, [134,
135] and protects oligodendrocytes from injury [136]. These
combined eﬀects might provide neuroprotective beneﬁt for
brain injury typical of preterm infants and term infants
withhypoxic-ischemicinjury.PhaseI/IIstudiestodetermine
safety and pharmacokinetics have been done [137, 138], and
further phase II/III studies are underway or in the planning
stages.
13.2. Melatonin. Melatonin (N-acetyl-5-methoxytrypta-
mine) is a naturally occurring hormone which regulates
circadian rhythms. Melatonin has antioxidant [139]a n d
antiapoptotic eﬀects [140, 141]. Prenatally administered
low-dose melatonin can reduce cerebral inﬂammation and
apoptosis following birth asphyxia in the spiny mouse [142].
In a fetal sheep model of perinatal asphyxia, melatonin
attenuates the production of 8-isoprostanes and reduces
activated microglia cells and TUNEL-positive cells in the
brain [143]. In a neonatal rodent model of LPS-induced
hypoxic-ischemic injury, multiple low-dose treatments with
melatonin reduced injury by 45%, but higher dose treatment
was not protective [144]. Clinically, melatonin has shown
beneﬁcial eﬀects when given to both asphyxiated [145]a n d
septic children [146].
13.3. Curcumin. Curcumin, the main active ingredient in
turmeric, can prevent the onset of inﬂammation by inhibit-
ing activation of NFκB, production of TNF-α,I F N - γ,a n d
NO, expression of iNOS, and activation of nicotinamide
adenine dinucleotide phosphate-oxidase (NOX) [147, 148].
Curcumin has been demonstrated to have a protective eﬀect
associated with suppression of iNOS and NOX activation
injury in a neonatal rat model of LPS-induced WMI [149].Neurology Research International 9
Table 1: Gaps in knowledge regarding human perinatal brain injury.
Barriers to Accessing the Brain
(i) Do pathogens, inﬂammatory mediators and inﬂammatory cells access the fetal and neonatal brain using the same
mechanisms as in animal and adult models?
Infection
(i) Which leukocyte populations and which speciﬁc proinﬂammatory cytokines are the primary triggers for brain damage of
premature infants?
(ii) What is the origin and the role of proteins diﬀerentially expressed in amniotic ﬂuid associated with chronic
chorioamnionitis cases compared to acute chorioamnionitis in the amniotic ﬂuid detected by proteomic analysis?
(iii) What is the role of microglial IL-1β signaling and TIMP expression in perinatal brain inﬂammation and repair?
(iv) What are the mechanisms of brain injury from LPS-activated microglia leading to PVL?
Cerebral Palsy
(i) What are the roles of inﬂammatory cytokines in preterm infants that develop CP?
(ii) To what extent does an altered inﬂammatory response and persistent neuroinﬂammation originating in the perinatal period
play a long-term role in preterm children with PVL-induced CP?
Dual Role of Cytokines
(i) What variables determine neuroprotective and neuroinﬂammatory properties of cytokines (e.g., timing, type, location, and
duration of injury)?
Cytokines and Genetic Susceptibility to Perinatal Brain Injury
(i) Which cytokine gene polymorphisms predispose to CP?
(ii) How do cytokine gene polymorphisms interact with perinatal infections to cause CP?
Cytokine Biomarkers of Perinatal Brain Injury
(i) Are there accurate diagnostic, predictive, and prognostic cord blood and neonatal plasma cytokines biomarkers that reﬂect
CSF cytokine levels or inﬂammatory events within the brain?
(ii) Are there biomarkers speciﬁc for precise inﬂammatory conditions associated with white matter injury (e.g., diﬀerentiating
between septicemia and necrotizing enterocolitis) that will provide time-sensitive, pathogen and treatment speciﬁc information?
Prevention and Treatment of Perinatal Brain Injury
(i) Which anti-inﬂammatory cytokines and treatments will safely and eﬀectively alter cytokine proﬁles promoting
neuroprotection and repair?
(ii) What is the optimal timing of such treatments?
Abbreviations: TIMP: tissue inhibitors of metalloproteinases, LPS: lipopolysaccharide, PVL: periventricular leukomalacia, CP: cerebral palsy, CSF:
cerebrospinal ﬂuid.
14.TargetingtheBBB toFight Disease
Another approach to preventing or treating neonatal brain
injury might be to target the BBB. Several neonatal pa-
thologies involve increased leakiness or dysfunction of the
BBB. Therefore, using agents that improve BBB function
might improve outcomes. Steroids, hypothermia, intracel-
lular cyclic AMP, adrenomedullin, and noradrenergic agents
all stimulate an increase in BBB function. These approaches
are under investigation or used therapeutically to treat some
adult brain disorders. For example, dexamethasone treat-
mentiscurrentlyusedtodecreasethebrainedemaassociated
with brain tumors [150], and Ca2+ c h a n n e lb l o c k e r sa r e
under investigation as treatment for hypoxia-induced brain
injury [151, 152]. Hypothermia, which also improves BBB
function, is one of the few proven therapies available to
treat neonates with hypoxic-ischemic brain injury and has
the lowest number needed to treat to see beneﬁt [153].
Stabilizing activated mast cells with disodium cromoglycate
(Cromolyn)maydecreaseBBBleakinessbyinhibitingrelease
of potentially toxic factors including histamine, serotonin,
neutral proteases, cytokines, chemokines, and free radicals
[154, 155].
Another approach under investigation in adult models
of disease is to improve the health of the endothelial cells
involved in maintenance of the BBB. The use of exercise,
ﬁsh oils, and speciﬁc fruits, soy, vitamins C an E, and
red wine may all be of beneﬁt (NNT = 7–9) [25]. The
application of a select group of these strategies might be
applicable to neonatal brain injury; however, each one must
be studied with regard to safety, eﬃcacy, and developmental
implications.
15. Conclusion
Large knowledge gaps exist regarding the detailed roles
of cytokines in brain injury, repair, and protection in
the human fetus/neonate. Although animal studies have
demonstrated an important role of cytokines in brain
injury, many questions on the underlying cytokine-related
mechanisms inﬂuencing brain injury remain unanswered.
In humans, the fetal/neonatal brain injury knowledge gap
is even wider (Table 1), with developmental diﬀerences
in immune response and in the complex neurovascular
barrier mechanisms that play a critical role in regulating
inﬂammatory mediator traﬃc at the interface between10 Neurology Research International
the systemic circulation and the brain. Understanding the
balance between pro- and anti-inﬂammatory mediators and
their roles in normal brain development and in the setting
of inﬂammation is needed to tailor treatments that promote
neuroprotection.
Future large animal studies aimed at developing diag-
nostic cytokine proﬁles of perinatal brain injury biomarkers
must be designed to allow evaluation in the context that
is clinically useful. While neonatal rodents models of brain
injury provide vital information about mechanisms of
brain injury and also neuroprotection, it is essential that
information learned in these models be veriﬁed in larger
animal models (fetal sheep, piglet, and nonhuman primate)
that more closely reﬂect human brain development.
For example, for early-hospital diagnosis, a test that is
reasonably speciﬁc and very sensitive to early perinatal brain
injury secondary to infection or cytokines/inﬂammation
would be necessary to facilitate time-sensitive anti-inﬂam-
matory strategies. Such a study should be speciﬁcally
designed to address the incremental beneﬁts of biomarker-
based information beyond traditional means of assessment,
such as standardized clinical examination, maternal history,
risk factor assessment, and radiographic studies. For pur-
poses of identifying risk of early deterioration, additional
data might be obtained by serial measurements in the
early hospital setting. Similarly, for functional prognosis,
serial testing in the subacute setting might provide useful
information. Patient heterogeneity (e.g., genetic factors),
and the timing, type, degree, and duration of perinatal
brain exposure to inﬂammatory mediators/cytokines likely
inﬂuence long-term neurodevelopmental outcomes. The
need for accurate biomarkers is well illustrated by infants
aﬀected by neonatal encephalopathy secondary to hypoxic
ischemic encephalopathy. Over 1500 neonates have now
been enrolled in randomized controlled trials of therapeu-
tic hypothermia using the best available entry criteria:a
combination of clinical assessments (Apgar scores, Sarnat
or Thompson scores), laboratory assessment (lactic acid,
pH, base deﬁcit) and electrophysiologic function [153].
While these criteria identify a group of high risk neonates,
their predictive value is poor: untreated, one-third of these
infants do well with no long-term neurodevelopmental
sequelae, while two thirds die or have signiﬁcant long-
term neurodevelopmental impairment. Treatment improves
outcomes by approximately 15%, but the infants who will
beneﬁt cannot currently be diﬀerentiated from those who
will not, nor from those who will do well without treatment.
Similarly, it is unlikely that one single biomarker, such
as a cytokine, will be robust enough to have clinical utility
for guiding treatment of infants with perinatal brain injury.
A panel of biomarkers will therefore likely be more useful.
Ideally, future biomarker biomarkers, which incorporate
serum cytokine levels and imaging modalities will allow for
early tailored individualized treatment strategies that will
promote the proper treatment for the proper patient at the
proper time. Similarly, in the subacute setting, a biomarker
panel might be useful adjunctive tool combined with clinical
information and radiographic imaging to determine risk
stratiﬁcation to direct aggressiveness of care for primary or
secondary prevention of perinatal brain injury in patients
with known risk factors.
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